Usa India city Mumbai Usa India city Mumbai

Lupin Q4 margins show improvement on lower R&D spend but growth seems priced in

Reading now: 960
www.livemint.com

MUMBAI: Lupin Ltd managed a decent performance in the fourth quarter, with revenues just about in sync with analysts expectations but its gross margin was not quite what the Street was looking forward to.

This drove its shares down about 2% in Friday's trade. Its US revenues were healthy, growing 14.7% sequentially. Some of this can be attributed to stocking up in the US which not only perked up sales in the geography but pushed up the proportion to about 42% of total revenue.

Most of the growth in Q4 last year stemmed from a one-time sale of products. At home, the company outpaced the Indian market’s growth rate thanks to secular growth tailwinds deepening the penetration of drugs in the country.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA